(2023)
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.
ESMO OPEN.
8,
6
(2023)
Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations.
CANCERS.
15,
22
(2023)
Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement.
CANCER RESEARCH AND TREATMENT.
55,
4
(2023)
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer.
JOURNAL OF THORACIC ONCOLOGY.
18,
9
(2023)
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
CANCER RESEARCH AND TREATMENT.
55,
2
(2022)
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
Cancer Medicine.
11,
15
(2022)
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.
EUROPEAN JOURNAL OF CANCER.
169,
-
(2022)
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
ONCOLOGY.
100,
4
(2022)
Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
CANCER.
128,
11
(2022)
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study.
ESMO OPEN.
7,
1
(2022)
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.
CLINICAL CANCER RESEARCH.
28,
11
(2021)
Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment.
TRANSLATIONAL LUNG CANCER RESEARCH.
10,
11
(2021)
Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery.
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY.
64,
2
(2021)
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer.
KOREAN JOURNAL OF INTERNAL MEDICINE.
36,
.
(2021)
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
CANCER IMMUNOLOGY IMMUNOTHERAPY.
-,
-
(2021)
Immunological characteristics of hyperprogressive disease in patients with non-small cell lung cancer treated with anti-pd-1/pd-l1 abs.
Immune Network.
20,
6
(2020)
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
BRITISH JOURNAL OF CANCER.
123,
12
(2020)
Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer.
SCIENTIFIC REPORTS.
10,
1
(2020)
Evaluating entrectinib as a treatment option for non-small cell lung cancer.
EXPERT OPINION ON PHARMACOTHERAPY.
21,
16
(2020)
Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY.
58,
5
